Skip to content

Released Aug 12, 2014, after the close

10-Q filed Aug 12, 2014, 43 days after period end · 0001104659-14-059898

Q2 2014 · 10-Q
Revenue—
Net Income-$6.07MN/M vs Q2 2013N/M vs Q1 2014
EPS Diluted-$0.30N/M vs Q2 2013N/M vs Q1 2014
Operating Income-$6,040,000N/M
Operating Cash Flowderived-$5,489,000N/M
Free Cash Flowderived-$5,515,000N/M

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ2 2014Q2 2013Q2 2012
Revenue—$290.00K$1.08M
Net Income-$6.07M-$5.53M-$2.74M
EPS Diluted-$0.30-$4.46-$2.58

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR